EMD Lexigen Research Center Corp.
|EMD Lexigen Research Center Corp. Patent applications|
|Patent application number||Title||Published|
|20080311655||Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation - Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.||12-18-2008|
Patent applications by EMD Lexigen Research Center Corp.